Infinity Pharmaceuticals, Inc.
) announced positive results from two phase I studies on IPI-145,
being developed for the treatment of patients suffering from
relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) and
chronic lymphocytic leukemia (CLL). Investors reacted positively
to the news and shares were up 2.6% on Dec 9.
ACTELION LTD (ALIOF): Get Free Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
INFINITY PHARMA (INFI): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.
Infinity Pharma announced results from a phase I study on IPI-145
in patients suffering from iNHL, a potentially fatal hematologic
malignancy (blood cancer). Results from the study revealed an
overall response rate of 73% including three complete responses
in patients receiving IPI-145. Additionally, data showed that 53%
patients were progression free for more than a year.
The company presented these data at the 55th annual meeting of
the American Society of Hematology (ASH). Results from the study
support Infinity Pharma's ongoing phase II DYNAMO study of
IPI-145 in patients suffering from refractory iNHL.
Infinity Pharma is currently enrolling patients for its DYNAMO
study (n=120). The study will evaluate the safety and efficacy of
IPI-145 in iNHL patients whose disease is refractory to
radioimmunotherapy or to both
Biogen Idec Inc.
) Rituxan (rituximab) and chemotherapy and who have progressed
within six months of receiving their last therapy. The primary
objective of the study is to evaluate the response rate according
to the International Working Group (IWG) criteria.
Infinity Pharma also announced results from a phase I study on
IPI-145 in patients suffering from CLL, another potentially fatal
hematologic malignancy (blood cancer). Results from this study
revealed that a nodal response rate of 89% and an overall
response rate of 48%, as defined by the International Workshop on
Chronic Lymphocytic Leukemia (IWCLL) criteria1, were observed in
patients treated with IPI-145.
IPI-145 was also generally well tolerated in the study. Results
from the study also support Infinity Pharma's phase III DUO study
(n=300) on IPI-145 in patients suffering from relapsed/refractory
CLL. The DUO study will evaluate the safety and efficacy of
IPI-145 in CLL patients. The main objective of the study is to
evaluate progression-free survival in these patients.
We are encouraged by Infinity Pharma's progress with its
pipeline. We expect investor focus to remain on the company's
pipeline going forward.
Infinity Pharma carries a Zacks Rank #2 (Buy). Some other stocks
worth considering include Zacks Ranked #1 (Strong Buy)